Quincy Bioscience, LLC v. Ellishbooks

Procedural entryThis page is a short order in Quincy Bioscience, LLC v. Ellishbooks. Read the opinion of the Court — 957 F.3d 725
Court of Appeals for the Seventh Circuit·Decided June 5, 2020·No. 19-1799·Published

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 19-1799 QUINCY BIOSCIENCE, LLC, Plaintiff-Appellee, v.

ELLISHBOOKS, et al., Defendants-Appellants. ____________________

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:17-cv-08292 — Sharon Johnson Coleman, Judge. ____________________

DECIDED JUNE 5, 2020 ____________________

Before WOOD, Chief Judge, and FLAUM and RIPPLE, Circuit Judges. PER CURIAM. On April 24, 2020, we issued an opinion af- firming the judgment in favor of the appellee, Quincy Bio- science, LLC (“Quincy”). See Quincy Bioscience, LLC v. Ellish- books, 957 F.3d 725, 726 (7th Cir. 2020). Quincy now seeks an award of sanctions under Federal Rule of Appellate Proce- dure 38. For the reasons stated below, the motion is granted. 2 No. 19-1799

Quincy brought this action against Ellishbooks and relat- ed individuals and entities (collectively “Ellishbooks”), al- leging violations of the Lanham Act, 15 U.S.C. §§ 1114, 1125, and various state laws. Specifically, Quincy alleged that El- lishbooks engaged in the unauthorized and unlawful sale of Quincy’s dietary supplements bearing the Prevagen® trademark, some of which had been stolen from retail out- lets. Ellishbooks did not respond to the complaint, and the district court entered a default. Quincy then moved for entry of default judgment. El- lishbooks opposed the motion on two grounds: (1) that it had not been served properly with the summons and com- plaint; and (2) that the products it had sold were distinct from those sold by Quincy. The district court rejected these arguments. It detailed the many ways in which Quincy had attempted to effectuate personal service, and observed that Ellishbooks had “deliberately … sought to evade service.”1 The district court concluded that service on Ellishbooks’s registered agent was legally adequate and that it had per- sonal jurisdiction over Ellishbooks. The court further ob- served that Ellishbooks had neither established good cause for its default nor identified a potentially meritorious de- fense. Accordingly, the district court entered a default judg- ment in favor of Quincy. The district court then scheduled a prove-up hearing to determine the amount of Quincy’s damages. Ellishbooks re- tained new counsel to represent it at the prove-up hearing. Before the hearing, Quincy submitted documents establish- ing that Ellishbooks had received $480,968.13 from selling

1 R.28 at 3. No. 19-1799 3

Prevagen® brand products. At the prove-up hearing, Ellish- books’s counsel argued against the award of damages, but did not counter Quincy’s evidence. The district court ulti- mately awarded Quincy $480,968.13 plus costs. The court’s order did not address Quincy’s request for a permanent in- junction, however, and Quincy moved to amend the judg- ment to include injunctive relief. The court held a hearing on the motion, but counsel for Ellishbooks did not appear. The court granted Quincy’s motion and permanently enjoined Ellishbooks from infringing on Quincy’s trademark and sell- ing stolen products bearing the Prevagen® mark. On appeal, Ellishbooks challenged the district court’s judgment on several grounds. Ellishbooks argued that the district court failed to make “factual findings on decisive is- sues” as required by Federal Rule of Civil Procedure 52(a).2 It further argued that the district court clearly erred in find- ing that Ellishbooks knew or had reason to know that some portion of the Prevagen® products it sold were stolen. Final- ly, it relatedly argued that the district court erred in entering a permanent injunction without requiring Quincy to estab- lish that Ellishbooks knew that some of the Prevagen® products were stolen. We concluded that Ellishbooks’s arguments “have been waived and, in any event, are meritless,” and “require lim- ited discussion.” Quincy Bioscience, LLC, 957 F.3d at 726, 729. Because of the default, the well-pleaded allegations of the complaint relating to liability were taken as true, including Quincy’s allegation that Ellishbooks had reason to know that the Prevagen® products it sold had been stolen from retail

2 Appellants’ Br. 5. 4 No. 19-1799

outlets. We deemed Ellishbooks’s remaining two arguments to be waived because they had not been made in the district court. We therefore affirmed the district court’s judgment in all respects. In its motion for sanctions, Quincy now submits that such an award is warranted because Ellishbooks’s appellate arguments were destined to fail. Rule 38 permits the court to award “just damages and single or double costs to the appel- lee” when an appellant files a frivolous appeal. Fed. R. App. 38. “An appeal is frivolous if the appellant’s claims are cur- sory, totally undeveloped, or reassert a previously rejected version of the facts.” McCurry v. Kenco Logistics Servs., LLC, 942 F.3d 783, 791 (7th Cir. 2019). “An appeal is also frivolous if it presents arguments that are so insubstantial that they are guaranteed to lose.” Id. Even when an appeal is frivo- lous, whether to impose sanctions under Rule 38 is a discre- tionary determination. Dolin v. GlaxoSmithKline LLC, 951 F.3d 882, 888 (7th Cir. 2020) (“When an appeal is frivolous, Rule 38 sanctions are not mandatory but are left to the sound discretion of the court of appeals to decide whether sanc- tions are appropriate.” (quoting Harris N.A. v. Hershey, 711 F.3d 794, 802 (7th Cir. 2013))). Ellishbooks, represented by new counsel, filed a response to Quincy’s motion. It suggests that attorneys’ fees are not authorized by Rule 38. This position is incorrect. See, e.g., Ja- worski v. Master Hand Contractors, Inc., 882 F.3d 686, 692 (7th Cir. 2018) (ordering appellant to pay appellees’ costs and at- torneys’ fees incurred in the appeal under Rule 38); Cooney v. Casady, 735 F.3d 514, 524 (7th Cir. 2013) (ordering appellant to show cause why it should not be required “under Rule 38 of the Federal Rules of Appellate Procedure to pay the de- No. 19-1799 5

fendants’ costs and reasonable attorneys’ fees on appeal”). Ellishbooks appears to confuse the issue of sanctions under Rule 38 with taxable costs under Federal Rule of Appellate Procedure 39 and 28 U.S.C. § 1920, which is a separate mat- ter. Ellishbooks also submits that it has not acted in bad faith at any point during this litigation.

Free access — add to your briefcase to read the full text and ask questions with AI

Quincy Bioscience, LLC v. Ellishbooks, (7th Cir. 2020).

Quincy Bioscience, LLC v. Ellishbooks (Quincy Bioscience, LLC v. Ellishbooks) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Harris N.A. v. Loren W. Hershey
711 F.3d 794 (Seventh Circuit, 2013)
Dariusz Jaworski v. Master Hand Contractors, Inc.
882 F.3d 686 (Seventh Circuit, 2018)
Edith McCurry v. Kenco Logistic Services, LLC
942 F.3d 783 (Seventh Circuit, 2019)
Wendy Dolin v. GlaxoSmithKline LLC
951 F.3d 882 (Seventh Circuit, 2020)
Quincy Bioscience, LLC v. Ellishbooks
957 F.3d 725 (Seventh Circuit, 2020)
H.A.L. NY Holdings, LLC v. Joseph Guinan, Jr.
958 F.3d 627 (Seventh Circuit, 2020)
Cooney v. Casady
735 F.3d 514 (Seventh Circuit, 2013)
In re Nora
778 F.3d 662 (Seventh Circuit, 2015)
Matter Of Lisse
921 F.3d 629 (Seventh Circuit, 2019)
Weinhaus v. Illinois
140 S. Ct. 1116 (Supreme Court, 2020)